Reduced GLP-1R expression in gastric glands of patients with type 2 diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages E1691-E1695

  Broide, E ^a,b   Bloch, O ^a,b   Ben Yehudah, G ^a,b   Cantrell, D ^a,b   Shirin, H ^a,b   Rapoport, M J ^a,b  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; MESSENGER RNA; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR;

ADULT; AGE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; SENSITIVITY ANALYSIS; STOMACH ANTRUM; STOMACH BIOPSY; STOMACH GLAND; STOMACH MUCOSA; STOMACH PARIETAL CELL; AGED; BIOPSY; CYTOLOGY; DIGESTIVE TRACT ENDOSCOPY; ENTEROENDOCRINE CELL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; BIOPSY; DIABETES MELLITUS, TYPE 2; ENDOSCOPY, DIGESTIVE SYSTEM; ENTEROENDOCRINE CELLS; FEMALE; GASTRIC MUCOSA; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; PARIETAL CELLS, GASTRIC; RECEPTORS, GLUCAGON; RNA, MESSENGER;

EID: 84907189195     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1114     Document Type: Article

References (20)

1. Vilsbøll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of type 2 diabetes mellitus. Dan Med Bull. 2004; 51: 364-370.
2. Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: Systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56: 965-972.
3. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on -cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52: 380-386.
4. Xu G, Kaneto H, Laybutt DR, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: Possible contribution to impaired incretin effects in diabetes. Diabetes. 2007;56: 1551-1558.
5. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: The extrapancreatic effects of glucagon- like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009;94: 1843-1852.
6. Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut. 1997;40: 597-601.
7. Wei Y, Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand. 1996;157: 355-357.
8. Hansen AB, Gespach CP, Rosselin GE, Holst JJ. Effect of truncated glucagon-like peptide 1 on cAMP in rat gastric glands and HGT-1 human gastric cancer cells. FEBS Lett. 1988;236: 119-122.
9. Broide E, Bloch O, Ben-Yehudah G, Cantrell D, Shirin H, Rapoport M. GLP-1 receptor is expressed in human stomach mucosa: Analysis of its cellular association and distribution within gastric glands. J Histochem Cytochem. 2013;61: 649-658.
10. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.AmJ Surg Pathol. 1996;20: 1161-1181.
11. Dixon WJ (chief editor). BMDP Statistical Software. Los Angeles, CA: University of California Press; 1993.
12. Højberg PV, Zander M, Vilsbøll T, et al. Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucoseinduced insulin secretion in patients with type 2 diabetes. Diabetologia. 2008;51: 632-640.
13. Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Juul Holst J, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety- effect of obesity and weight reduction. Int J Obes Relat Metab Disord. 2001;25: 1206-1214.
14. Beinborn M, Worrall CI, McBride EW, Kopin AS. A human glucagon- like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept. 2005;130(1-2): 1-6.
15. Meier JJ, Nauck MA, Kask B, et al. Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls. World J Gastroenterol. 2006;12: 1874-1880.
16. Bastaki SM, Adeghate E, Chandranath IS, et al. Effects of streptozotocin- induced long-term diabetes on parietal cell function and morphology in rats. Mol Cell Biochem. 2010;341: 43-50.
17. Hasler WL, Coleski R, Chey WD, et al. Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: Relation to degree of gastric retention. Am J Physiol Gastrointest Liver Physiol. 2008; 294: G1384-G1391.
18. Lam WF, Masclee AA, Muller ES, Lamers CB. Effect of hyperglycemia on gastric acid secretion during the gastric phase of digestion. Am J Physiol. 1997;272: G1116-G1121.
19. Jia X, Brown JC, Kwok YN, Pederson RA, McIntosh CH. Gastric inhibitory polypeptide and glucagon-like peptide-1(7-36) amide exert similar effects on somatostatin secretion but opposite effects on gastrin secretion from the rat stomach. Can J Physiol Pharmacol. 1994;72: 1215-1219.
20. Tseng PH, Lee YC, Chiu HM, et al. Association of diabetes and HbA1c levels with gastrointestinal manifestations. Diabetes Care. 2012;35: 1053-1060.